The European Medicines Agency has granted approval to OMRIX Biopharmaceuticals, Inc.’s liquid fibrin sealant, Evicel. The product can now be marketed in Europe for supportive therapy in surgery for hemostasis. It is currently sold in the US markets by a Johnson & Johnson division. EVICEL, with this approval, is licensed for commercialization in the 27 countries coming under the European Union. This easy and ready to use liquid does not contain aprotinin, preventing any adverse effects.